Translation

PATENT COOPERATION TREATY

Wenderoth (USA)

PCT/JP2003/013707

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Tyeaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCT-0319	FOR FURTHER AC	TION	See Form PCT/IPEA/416			
• • • • • • • • • • • • • • • • • • • •		e (day/month/year) 3 (27.10.2003)	Priority date (day/month/year) 29 October 2002 (29.10.2002)			
International Patent Classification (IPC) or r C07D 487/18, 498/18, 498/22, 5 35/00, 43/00	national classification and 15/18, 515/22, 519/00	d IPC), A61K 31/4995, 3	1/506, 31/517, 31/5377, 31/55, A61P			
Applicant BA	NYU PHARMACE	EUTICAL CO., L	TD.			
This report is the international preli Authority under Article 35 and tran	minary examination repo smitted to the applicant s	ort, established by this according to Article 3	s International Preliminary Examining 6.			
2. This REPORT consists of a total of 4 sheets, including this cover sheet						
3. This report is also accompanied by ANNEXES, comprising: a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the						
Administrative Instructions). 4. This report contains indications relating to the following items:						
Box No. I Basis of the report						
Box No. II Priority						
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of invention						
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited						
Box No. VII Certain defects in the international application						
Box No. VIII Certain observations on the international application						
Date of submission of the demand		Date of completion	of this report			
08 January 2004 (08.0	1.2004)	04	March 2004 (04.03.2004)			
Name and mailing address of the IPEA/JP		Authorized officer				
Facsimile No.		Telephone No.				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2003/013707

Box N	o. I	Basis of the report
1. With	h regan erwise i	d to the language, this report is based on the international application in the language in which it was filed, unless
	Thi	report is based on translations from the original language into the following language, th is language of a translation furnished for the purpose of:
		International search (under Rules 12.3 and 23.1(b))
	\sqcap	publication of the international application (under Rule 12.4)
ĺ		international preliminary examination (under Rules 55.2 and/or 55.3)
	_	(2000)
J	are not	d to the elements of the international application, this report is based on (replacement sheets which have been the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" annexed to this report):
		nternational application as originally filed/furnished
		escription:
	pages	, as originally mediumished
	pages	
		Total by and Fallmorthy on
		aims:
	pages	, as originary medyumished
	pages	as amended (together with any statement) under Article 19
	pages	10001103 by mile Anniothy off
\Box	•	the state of the s
Ш		awings;
	pages	, as originally filed/furnished
	pages	- Isostron by this Adminity off
	a seda	cince listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
		•
3	The a	mendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos.
		the drawings, sheets/figs
		the sequence listing (specify):
		any table(s) related to sequence listing (specify):
	(Rule 1	sport has been established as if (some of) the amendments annexed to this report and listed below had not been since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box 70.2(c)).
	ן ַן	he description, pages
	╚	he claims, Nos.
	، ليا	he drawings, sheets/figs
	╚	he sequence listing (specify):
	∐ a	ny table(s) related to sequence listing (specify):
• If item	4 appl	ies, some or all of those sheats may be marked "superseded."

international preliminary report on patentability

International applic	ation No.
----------------------	-----------

PCT/JP03/13707

Statement			
Novelty (N)	Claims	1-16	YES
·	Claims	·	NO NO
Inventive step (IS)	Claims	1-16	YES
	Claims		No No
Industrial applicability (IA)	Claims	1-16	
	Claims	1-10	YES NO

2. Citations and explanations (Rule 70.7)

Document 1: WO, 02-02550, A1 (Banyu Pharmaceutical Co., Ltd.), 10 January, 2002 (10.01.02)

Document 2: JP, 2002-220338, A (Banyu Pharmaceutical Co., Ltd.), 9 August, 2002 (09.08.02) Document 3: WO, 98-33798, A2 (Warner Lambert Co.), 6 August, 1998 (06.08.98)

Claims 1-16

The subject matters of claims 1-16 appear to be novel and to involve an inventive step in view of documents 1-3 cited in the ISR.

The invention described in the present international application relates to compounds represented by general formula (I), and a cdk inhibitor, anti-cancer drug and the like respectively containing any of the compounds as an active ingredient. The subject matters of the above-mentioned claims appear to be novel, since they are not disclosed in any of the documents cited in the ISR. Furthermore, none of the documents suggests or describes them. Especially, the subject matters of those claims are different from the inventions described in documents 1-3 in the constitution in which the compounds of general formula (I) have

Form PCT/ IPEA/409 (Box No. V) (January 2004)